Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats.

Enomoto M, Mantyh PW, Murrell J, Innes JF, Lascelles BDX.

Vet Rec. 2019 Jan 5;184(1):23. doi: 10.1136/vr.104590. Epub 2018 Oct 27. Review.

2.

Mechanisms that drive bone pain across the lifespan.

Mantyh PW.

Br J Clin Pharmacol. 2019 Jun;85(6):1103-1113. doi: 10.1111/bcp.13801. Epub 2018 Nov 22. Review.

PMID:
30357885
3.

Anti-nerve growth factor does not change physical activity in normal young or aging mice but does increase activity in mice with skeletal pain.

Majuta LA, Mitchell SAT, Kuskowski MA, Mantyh PW.

Pain. 2018 Nov;159(11):2285-2295. doi: 10.1097/j.pain.0000000000001330.

PMID:
29994990
4.

New Insights in Understanding and Treating Bone Fracture Pain.

Mitchell SAT, Majuta LA, Mantyh PW.

Curr Osteoporos Rep. 2018 Aug;16(4):325-332. doi: 10.1007/s11914-018-0446-8. Review.

PMID:
29948820
5.

The Changing Sensory and Sympathetic Innervation of the Young, Adult and Aging Mouse Femur.

Chartier SR, Mitchell SAT, Majuta LA, Mantyh PW.

Neuroscience. 2018 Sep 1;387:178-190. doi: 10.1016/j.neuroscience.2018.01.047. Epub 2018 Feb 10.

6.

Mice with cancer-induced bone pain show a marked decline in day/night activity.

Majuta LA, Guedon JG, Mitchell SAT, Kuskowski MA, Mantyh PW.

Pain Rep. 2017 Aug 11;2(5):e614. doi: 10.1097/PR9.0000000000000614. eCollection 2017 Sep.

7.

Immunohistochemical localization of nerve growth factor, tropomyosin receptor kinase A, and p75 in the bone and articular cartilage of the mouse femur.

Chartier SR, Mitchell SA, Majuta LA, Mantyh PW.

Mol Pain. 2017 Jan-Dec;13:1744806917745465. doi: 10.1177/1744806917745465. Epub 2017 Nov 22.

8.

Anti-nerve growth factor therapy increases spontaneous day/night activity in mice with orthopedic surgery-induced pain.

Majuta LA, Guedon JG, Mitchell SA, Ossipov MH, Mantyh PW.

Pain. 2017 Apr;158(4):605-617. doi: 10.1097/j.pain.0000000000000799.

9.

AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions.

Paice JA, Mulvey M, Bennett M, Dougherty PM, Farrar JT, Mantyh PW, Miaskowski C, Schmidt B, Smith TJ.

J Pain. 2017 Mar;18(3):233-246. doi: 10.1016/j.jpain.2016.10.020. Epub 2016 Nov 21. Review.

11.

The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain.

Slosky LM, BassiriRad NM, Symons AM, Thompson M, Doyle T, Forte BL, Staatz WD, Bui L, Neumann WL, Mantyh PW, Salvemini D, Largent-Milnes TM, Vanderah TW.

Pain. 2016 Nov;157(11):2605-2616.

12.

Dissociation between the relief of skeletal pain behaviors and skin hypersensitivity in a model of bone cancer pain.

Guedon JM, Longo G, Majuta LA, Thomspon ML, Fealk MN, Mantyh PW.

Pain. 2016 Jun;157(6):1239-47. doi: 10.1097/j.pain.0000000000000514.

13.

Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent.

Hanlon KE, Lozano-Ondoua AN, Umaretiya PJ, Symons-Liguori AM, Chandramouli A, Moy JK, Kwass WK, Mantyh PW, Nelson MA, Vanderah TW.

Breast Cancer (Dove Med Press). 2016 Apr 15;8:59-71. doi: 10.2147/BCTT.S100393. eCollection 2016.

14.

Sclerostin Immunoreactivity Increases in Cortical Bone Osteocytes and Decreases in Articular Cartilage Chondrocytes in Aging Mice.

Thompson ML, Jimenez-Andrade JM, Mantyh PW.

J Histochem Cytochem. 2016 Mar;64(3):179-89. doi: 10.1369/0022155415626499. Epub 2015 Dec 23.

15.

Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer.

Thompson ML, Jimenez-Andrade JM, Chartier S, Tsai J, Burton EA, Habets G, Lin PS, West BL, Mantyh PW.

Pain. 2015 Sep;156(9):1692-702. doi: 10.1097/j.pain.0000000000000228.

16.

Spinal dopaminergic projections control the transition to pathological pain plasticity via a D1/D5-mediated mechanism.

Kim JY, Tillu DV, Quinn TL, Mejia GL, Shy A, Asiedu MN, Murad E, Schumann AP, Totsch SK, Sorge RE, Mantyh PW, Dussor G, Price TJ.

J Neurosci. 2015 Apr 22;35(16):6307-17. doi: 10.1523/JNEUROSCI.3481-14.2015.

17.

Orthopedic surgery and bone fracture pain are both significantly attenuated by sustained blockade of nerve growth factor.

Majuta LA, Longo G, Fealk MN, McCaffrey G, Mantyh PW.

Pain. 2015 Jan;156(1):157-65. doi: 10.1016/j.pain.0000000000000017.

18.

NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use.

McCaffrey G, Thompson ML, Majuta L, Fealk MN, Chartier S, Longo G, Mantyh PW.

Cancer Res. 2014 Dec 1;74(23):7014-23. doi: 10.1158/0008-5472.CAN-14-1220. Epub 2014 Oct 6.

19.

Exuberant sprouting of sensory and sympathetic nerve fibers in nonhealed bone fractures and the generation and maintenance of chronic skeletal pain.

Chartier SR, Thompson ML, Longo G, Fealk MN, Majuta LA, Mantyh PW.

Pain. 2014 Nov;155(11):2323-36. doi: 10.1016/j.pain.2014.08.026. Epub 2014 Sep 6.

20.

Bone cancer pain: from mechanism to therapy.

Mantyh PW.

Curr Opin Support Palliat Care. 2014 Jun;8(2):83-90. doi: 10.1097/SPC.0000000000000048. Review.

21.

The ACTTION-American Pain Society Pain Taxonomy (AAPT): an evidence-based and multidimensional approach to classifying chronic pain conditions.

Fillingim RB, Bruehl S, Dworkin RH, Dworkin SF, Loeser JD, Turk DC, Widerstrom-Noga E, Arnold L, Bennett R, Edwards RR, Freeman R, Gewandter J, Hertz S, Hochberg M, Krane E, Mantyh PW, Markman J, Neogi T, Ohrbach R, Paice JA, Porreca F, Rappaport BA, Smith SM, Smith TJ, Sullivan MD, Verne GN, Wasan AD, Wesselmann U.

J Pain. 2014 Mar;15(3):241-9. doi: 10.1016/j.jpain.2014.01.004.

22.

The neurobiology of skeletal pain.

Mantyh PW.

Eur J Neurosci. 2014 Feb;39(3):508-19. doi: 10.1111/ejn.12462. Review.

23.

Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.

Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, Largent-Milnes TM, Havelin JJ, Ferland HL 3rd, Chandramouli A, Owusu-Ankomah M, Nikolich-Zugich T, Bloom AP, Jimenez-Andrade JM, King T, Porreca F, Nelson MA, Mantyh PW, Vanderah TW.

J Bone Miner Res. 2013 Jan;28(1):92-107. doi: 10.1002/jbmr.1732.

24.

Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature.

Reilly RM, McDonald HA, Puttfarcken PS, Joshi SK, Lewis L, Pai M, Franklin PH, Segreti JA, Neelands TR, Han P, Chen J, Mantyh PW, Ghilardi JR, Turner TM, Voight EA, Daanen JF, Schmidt RG, Gomtsyan A, Kort ME, Faltynek CR, Kym PR.

J Pharmacol Exp Ther. 2012 Aug;342(2):416-28. doi: 10.1124/jpet.111.190314. Epub 2012 May 8.

PMID:
22570364
25.

Sensory and sympathetic nerve fibers undergo sprouting and neuroma formation in the painful arthritic joint of geriatric mice.

Jimenez-Andrade JM, Mantyh PW.

Arthritis Res Ther. 2012 May 1;14(3):R101. doi: 10.1186/ar3826.

26.

Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint.

Ghilardi JR, Freeman KT, Jimenez-Andrade JM, Coughlin KA, Kaczmarska MJ, Castaneda-Corral G, Bloom AP, Kuskowski MA, Mantyh PW.

Arthritis Rheum. 2012 Jul;64(7):2223-32. doi: 10.1002/art.34385.

27.

Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain.

Jimenez-Andrade JM, Ghilardi JR, Castañeda-Corral G, Kuskowski MA, Mantyh PW.

Pain. 2011 Nov;152(11):2564-74. doi: 10.1016/j.pain.2011.07.020. Epub 2011 Sep 9.

28.

Antagonism of nerve growth factor-TrkA signaling and the relief of pain.

Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL.

Anesthesiology. 2011 Jul;115(1):189-204. doi: 10.1097/ALN.0b013e31821b1ac5.

29.

Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers.

Bloom AP, Jimenez-Andrade JM, Taylor RN, Castañeda-Corral G, Kaczmarska MJ, Freeman KT, Coughlin KA, Ghilardi JR, Kuskowski MA, Mantyh PW.

J Pain. 2011 Jun;12(6):698-711. doi: 10.1016/j.jpain.2010.12.016. Epub 2011 Apr 15.

30.

The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A.

Castañeda-Corral G, Jimenez-Andrade JM, Bloom AP, Taylor RN, Mantyh WG, Kaczmarska MJ, Ghilardi JR, Mantyh PW.

Neuroscience. 2011 Mar 31;178:196-207. doi: 10.1016/j.neuroscience.2011.01.039. Epub 2011 Jan 26.

31.

Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain.

Ghilardi JR, Freeman KT, Jimenez-Andrade JM, Mantyh WG, Bloom AP, Kuskowski MA, Mantyh PW.

Mol Pain. 2010 Dec 7;6:87. doi: 10.1186/1744-8069-6-87.

32.

Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain.

Jimenez-Andrade JM, Bloom AP, Stake JI, Mantyh WG, Taylor RN, Freeman KT, Ghilardi JR, Kuskowski MA, Mantyh PW.

J Neurosci. 2010 Nov 3;30(44):14649-56. doi: 10.1523/JNEUROSCI.3300-10.2010.

33.

The effect of aging on the density of the sensory nerve fiber innervation of bone and acute skeletal pain.

Jimenez-Andrade JM, Mantyh WG, Bloom AP, Freeman KT, Ghilardi JR, Kuskowski MA, Mantyh PW.

Neurobiol Aging. 2012 May;33(5):921-32. doi: 10.1016/j.neurobiolaging.2010.08.008. Epub 2010 Oct 13.

34.

Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers.

Ghilardi JR, Freeman KT, Jimenez-Andrade JM, Mantyh WG, Bloom AP, Bouhana KS, Trollinger D, Winkler J, Lee P, Andrews SW, Kuskowski MA, Mantyh PW.

Bone. 2011 Feb;48(2):389-98. doi: 10.1016/j.bone.2010.09.019. Epub 2010 Sep 18.

35.

Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain.

Mantyh WG, Jimenez-Andrade JM, Stake JI, Bloom AP, Kaczmarska MJ, Taylor RN, Freeman KT, Ghilardi JR, Kuskowski MA, Mantyh PW.

Neuroscience. 2010 Dec 1;171(2):588-98. doi: 10.1016/j.neuroscience.2010.08.056. Epub 2010 Sep 20.

36.

Bone cancer pain.

Jimenez-Andrade JM, Mantyh WG, Bloom AP, Ferng AS, Geffre CP, Mantyh PW.

Ann N Y Acad Sci. 2010 Jun;1198:173-81. doi: 10.1111/j.1749-6632.2009.05429.x. Review.

37.

A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.

Lozano-Ondoua AN, Wright C, Vardanyan A, King T, Largent-Milnes TM, Nelson M, Jimenez-Andrade JM, Mantyh PW, Vanderah TW.

Life Sci. 2010 Apr 24;86(17-18):646-53. doi: 10.1016/j.lfs.2010.02.014. Epub 2010 Feb 20.

38.

A phenotypically restricted set of primary afferent nerve fibers innervate the bone versus skin: therapeutic opportunity for treating skeletal pain.

Jimenez-Andrade JM, Mantyh WG, Bloom AP, Xu H, Ferng AS, Dussor G, Vanderah TW, Mantyh PW.

Bone. 2010 Feb;46(2):306-13. doi: 10.1016/j.bone.2009.09.013. Epub 2009 Sep 18. Erratum in: Bone. 2010 Jun;46(6):1670-1.

39.

Capsaicin-sensitive sensory nerve fibers contribute to the generation and maintenance of skeletal fracture pain.

Jimenez-Andrade JM, Bloom AP, Mantyh WG, Koewler NJ, Freeman KT, Delong D, Ghilardi JR, Kuskowski MA, Mantyh PW.

Neuroscience. 2009 Sep 15;162(4):1244-54. doi: 10.1016/j.neuroscience.2009.05.065. Epub 2009 May 29.

40.

New advances in musculoskeletal pain.

Bove SE, Flatters SJ, Inglis JJ, Mantyh PW.

Brain Res Rev. 2009 Apr;60(1):187-201. doi: 10.1016/j.brainresrev.2008.12.012. Epub 2008 Dec 25. Review.

41.

Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.

Honore P, Chandran P, Hernandez G, Gauvin DM, Mikusa JP, Zhong C, Joshi SK, Ghilardi JR, Sevcik MA, Fryer RM, Segreti JA, Banfor PN, Marsh K, Neelands T, Bayburt E, Daanen JF, Gomtsyan A, Lee CH, Kort ME, Reilly RM, Surowy CS, Kym PR, Mantyh PW, Sullivan JP, Jarvis MF, Faltynek CR.

Pain. 2009 Mar;142(1-2):27-35. doi: 10.1016/j.pain.2008.11.004. Epub 2009 Jan 9.

PMID:
19135797
42.

Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.

Halvorson KG, Sevcik MA, Ghilardi JR, Sullivan LJ, Koewler NJ, Bauss F, Mantyh PW.

J Pain Symptom Manage. 2008 Sep;36(3):289-303. doi: 10.1016/j.jpainsymman.2007.10.005. Epub 2008 Apr 14.

43.

Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies.

Jimenez-Andrade JM, Herrera MB, Ghilardi JR, Vardanyan M, Melemedjian OK, Mantyh PW.

Mol Pain. 2008 Mar 19;4:10. doi: 10.1186/1744-8069-4-10.

44.

A fracture pain model in the rat: adaptation of a closed femur fracture model to study skeletal pain.

Freeman KT, Koewler NJ, Jimenez-Andrade JM, Buus RJ, Herrera MB, Martin CD, Ghilardi JR, Kuskowski MA, Mantyh PW.

Anesthesiology. 2008 Mar;108(3):473-83. doi: 10.1097/ALN.0b013e3181649351.

PMID:
18292685
45.
46.

An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat.

Peters CM, Jimenez-Andrade JM, Kuskowski MA, Ghilardi JR, Mantyh PW.

Brain Res. 2007 Sep 7;1168:46-59. Epub 2007 Jul 17.

47.

Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture.

Jimenez-Andrade JM, Martin CD, Koewler NJ, Freeman KT, Sullivan LJ, Halvorson KG, Barthold CM, Peters CM, Buus RJ, Ghilardi JR, Lewis JL, Kuskowski MA, Mantyh PW.

Pain. 2007 Dec 15;133(1-3):183-96. Epub 2007 Aug 10.

PMID:
17693023
48.

The cerebral signature for pain perception and its modulation.

Tracey I, Mantyh PW.

Neuron. 2007 Aug 2;55(3):377-91. Review.

49.

Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur.

Koewler NJ, Freeman KT, Buus RJ, Herrera MB, Jimenez-Andrade JM, Ghilardi JR, Peters CM, Sullivan LJ, Kuskowski MA, Lewis JL, Mantyh PW.

J Bone Miner Res. 2007 Nov;22(11):1732-42.

50.

NK-1 receptors modulate the excitability of ON cells in the rostral ventromedial medulla.

Budai D, Khasabov SG, Mantyh PW, Simone DA.

J Neurophysiol. 2007 Feb;97(2):1388-95. Epub 2006 Dec 20.

Supplemental Content

Loading ...
Support Center